Roche announces new Corporate Executive Committee
William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and Daniel O’Day appointed COO Diagnostics Division – Jean-Jacques Garaud and Dan Zabrowski to become Members of Enlarged Executive Committee – Ian Clark appointed CEO Genentech
At the end of 2009 William M. Burns (62), CEO Pharma Division, Juergen Schwiezer (65), CEO Diagnostics Division, and Jonathan Knowles (62), Head Group Research, will resign from the Corporate Executive Committee. Juergen Schwiezer and Jonathan Knowles will retire, while William M. Burns, as announced previously, will be proposed as a Member of the Roche Board at the Annual Shareholder Meeting 2010.
William M. Burns started his career in 1986 with Roche UK. He has been a Member of the Corporate Executive Committee for ten years, thereof eight years as Head Pharma Division. Juergen Schwiezer joined Boehringer Mannheim in 1976 and was appointed Head of its Executive Committee in 1995. He became a Member of the Executive Committee Roche Germany in 1998 and was heading the Diagnostics Division as Member of the Roche Corporate Executive Committee since 2008. Prof. Jonathan Knowles was appointed Head Roche Research in 1997 and has been a Member of the Corporate Executive Committee since 1998.
Franz B. Humer, Chairman of the Roche Group, said: „William M. Burns, Jonathan Knowles and Juergen Schwiezer have significantly shaped Roche’s successful development over many years. All three have been instrumental in driving the Group’s overall success. We are deeply grateful for their tremendous contribution throughout their distinguished careers.”
The Board of Directors has made the following appointments, effective 1 January 2010:
Pascal Soriot (50), currently CEO Genentech and Member of the Corporate Executive Committee, is appointed Chief Operating Officer (COO) Pharma Division and assumes global responsibility for Pharma operations. These include commercial operations worldwide, global marketing, production, development and registration.
Jean-Jacques Garaud (54), currently Head Pharma Development, is appointed Member of the Enlarged Executive Committee and assumes responsibility for Roche Pharma Research and Early Development.
Dan Zabrowski (50), Head Pharma Partnering, is also appointed Member of the Enlarged Executive Committee.
As announced previously, Richard Scheller is a Member of the Enlarged Executive Committee. Based in San Francisco, he is responsible for Genentech Research and Early Development, which is managed as an independent unit.
Jean-Jacques Garaud, Richard Scheller and Dan Zabrowski report to Severin Schwan.
Daniel O’Day (45), currently Head Roche Molecular Diagnostics, is appointed Chief Operating Officer (COO) Diagnostics Division and Member of the Executive Committee. Burkhard Piper, Head Roche Diabetes Care, reports to Daniel O’Day.
Ian Clark (49), currently Head Global Product Strategy Pharma, will succeed Pascal Soriot as CEO Genentech. He will report to Pascal Soriot and will be based in South San Francisco.
Franz B. Humer, Chairman of the Roche Group commented: „We are proud to complement the Corporate Executive Committee with internal appointments having such an impressive track record. With this strong leadership team Roche will continue to be successful in the years ahead!”
Severin Schwan, CEO of the Roche Group, said: „Following the conclusion of the Genentech integration we will continue to bring innovative healthcare solutions to patients worldwide through a diversity of research approaches and through efficient global development and commercialization. This broadened and younger Corporate Executive Committee will continue to drive Roche’s long-term vision as the world’s leading biotech company.“
Effective 1 January 2010 Roche’s Corporate Executive Committee (CEC) will be composed as follows:
Severin Schwan Chief Executive Officer
Erich Hunziker Chief Financial Officer and Deputy Head of the CEC
Pascal Soriot COO Pharma Division
Daniel O’Day COO Diagnostics Division
Silvia Ayyoubi Head Human Resources
Gottlieb Keller General Counsel
Jean-Jacques Garaud* Head Roche Pharma Research & Early Development
Richard Scheller* Head Genentech Research & Early Development
Dan Zabrowski* Head Pharma Partnering
Osamu Nagayama* President and CEO Chugai Pharma
Per-Olof Attinger* Head Communications
* Member of the Enlarged Corporate Executive Committee
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80’000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.